Methylation of the regulatory region of the Elongation Of Very Long Chain Fatty Acids-Like 2 (ELOVL2) gene, an enzyme involved in elongation of long-chain polyunsaturated fatty acids, is one of the most robust biomarkers of human age, but the critical question of whether ELOVL2 plays a functional role in molecular aging has not been resolved.
INTRODUCTION
Chronological age predicts relative levels of mental and physical performance, disease risks across common disorders, and mortality 1 . The use of chronological age is limited, however, in explaining the considerable biological variation among individuals of a similar age. Biological age is a concept that attempts to quantify different aging states influenced by genetics and a variety of environmental factors. While epidemiological studies have succeeded in providing quantitative assessments of the impact of discrete factors on human longevity, advances in molecular biology now offer the ability to look beyond population-level effects and to hone in on the effects of specific factors on aging within single organisms.
A quantitative model for aging based on genome-wide DNA methylation patterns by using measurements at 470,000 CpG markers from whole blood samples of a large cohort of human individuals spanning a wide age range has recently been developed [2] [3] [4] . This method is highly accurate at predicting age, and can also discriminate relevant factors in aging, including gender, genetic variants, and disease 2, 5 . Several models work in multiple tissues 3, 4 , suggesting the possibility of a common molecular clock, regulated in part by changes in the methylome. In addition, these methylation patterns are strongly correlated with cellular senescence and aging 6 . The regulatory regions of several genes become progressively methylated with increasing chronological age, suggesting a functional link between age, DNA methylation, and gene expression. The promoter region of ELOVL2, in particular, was the first to be shown to reliably show increased methylation as humans age 7 , and confirmed in the one of the molecular clock models 2 .
ELOVL2 (Elongation Of Very Long Chain Fatty Acids-Like 2) encodes a transmembrane protein involved in the elongation of long-chain (C22 and C24) omega-3 and omega-6 polyunsaturated fatty acids (LC-PUFAs) 8 . Specifically, ELOVL2 is capable of converting docosapentaenoic acid (DPA) (22:5n-3) to 24:5n-3, which can lead to the formation of very long chain PUFAs (VLC-PUFAs) as well as 22:6n-3, docosahexaenoic acid (DHA) 9 . DHA is the main polyunsaturated fatty acid in the retina and brain. Its presence in photoreceptors promotes healthy retinal function and protects against damage from bright light and oxidative stress. ELOVL2 has been shown to regulate levels of DHA 10 , which in turn has been associated with age-related macular degeneration (AMD), among a host of other retinal degenerative diseases 11 . In general, LC-PUFAs are involved in crucial biological functions including energy production, modulation of inflammation, and maintenance of cell membrane integrity. It is, therefore, possible that ELOVL2 methylation plays a role in the aging process through the regulation of these diverse biological pathways.
In this study, we investigated the role of ELOVL2 in molecular aging in the retina. We find that the Elovl2 promoter region is increasingly methylated with age in the retina, resulting in age-related decreases in Elovl2 expression. These changes are associated with decreasing visual structure and function in aged mice. We then demonstrate that loss of ELOVL2-specific function results in the early-onset appearance of sub-RPE deposits that contain molecular markers found in drusen in AMD. This phenotype is also associated with visual dysfunction as measured by electroretinography, and it suggests that ELOVL2 may serve as a critical regulator of a molecular aging clock in the retina, which may have important therapeutic implications for diseases such as age-related macular degeneration.
RESULTS

Elovl2 expression is downregulated with age through methylation and is correlated with functional and anatomical biomarkers in aged wildtype mice
Previous studies showed that methylation of the promoter region of ELOVL2 is highly correlated with human age 2 . Methylation of regulatory regions is thought to prevent the transcription of neighboring genes and serves as a method to regulate gene expression.
We first wished to characterize whether the age-associated methylation of the ELOVL2 promoter previously found in human serum also occurs in the mouse. First, we analyzed ELOVL2 promoter methylation data obtained using bisulfite-sequencing in mouse blood and compared it to the available human data for the same region 12 and observed similar age-related increase in methylation level in the compared regions ( Figure S1A ). To assay methylation of the Elovl2 promoter in retina, we used methylated DNA immunoprecipitation (MeDIP) method 13 and tested the methylation levels in the CpG island in the Elovl2 regulatory region by quantitative PCR with Elovl2-specific primers (Supp . Table 1 ). MeDIP analysis of the CpG island in the Elovl2 regulatory region showed increasing methylation with age in the mouse retina ( Fig. 1A) . This was well-correlated with age-related decreases in expression of Elovl2 as assessed by Western blot and qPCR ( Fig. 1B and Fig S1B,C) indicating the potential role of age-related changes in DNA methylation in Elovl2 expression.
To understand the cell-type and age-specific expression of Elovl2, we performed in situ hybridization with an Elovl2 RNAscope probe on mouse retina sections 14 . In three-monthold and in 22-month-old mice, we noticed Elovl2 expression in the photoreceptor layer, particularly in the cone layer as well as the RPE (Fig. 1C and Fig. S1E ). We observed that the expression of Elovl2 on mRNA level in RPE was lower than in the retina ( Fig.   S1D ). Importantly, at older stages (22-month animals), we noticed Elovl2 mRNA in the same locations but dramatically reduced in expression ( Fig. 1C) . As Elovl2 is also highly expressed in the liver, we performed a time course of Elovl2 expression in this tissue. We observed similar age-related decreases in Elovl2 expression correlated with increases in methylation of the Elovl2 promoter in mouse liver, indicating that age-associated methylation of Elovl2 occurs in multiple tissues in mice ( Fig. S1F) .
Visual function is highly correlated with age, including age-related decreases in rod function in both humans and mice 15, 16 . In addition, autofluorescent aggregates have been observed in the fundus of aged mice, suggesting that these aggregates may also be an anatomical surrogate of aging in the mouse retina 17,18 . To measure and correlate these structural and visual function changes with age in mice, we performed an analysis of wildtype C57BL/6J mice at various timepoints through development, using fundus autofluorescence and electroretinography (ERG) as structural and functional readouts for vision. We observed increasing amounts of autofluorescent aggregates on fundus autofluorescence imaging with increasing mouse age, most prominently at two years (Fig. Fig. S1G ). We also detected an age-associated decrease in visual function, as measured by maximum scotopic amplitude by ERG ( Fig. 1F and Fig. S1H ), as shown in previous studies 15, 19 . These data show that an age-associated accumulation of autofluorescent spots and decrease of visual function as detected by ERG correlate with Elovl2 downregulation in the mouse retina.
1D, E and
Manipulating ELOVL2 expression causes age-related changes in cells
The WI38 and IMR90 cell lines are well-established cell models of aging 20 . We used these cell lines to further explore the effect of ELOVL2 promoter methylation on cell health. First, using MeDIP, we found that promoter methylation increased with cell population doubling ( Fig. 2A) further confirming strong correlation between increased ELOVL2 methylation and aging. Since the methylation of the promoter region was shown to be inhibitory for transcription 21 , we investigated whether the expression level of ELOVL2 inversely correlated with ELOVL2 promoter methylation. Using qRT-PCR, we found that the expression level of the gene decreased with increasing population doubling (PD) number (Fig. 2B) ). We conclude that ELOVL2 expression is downregulated in aging cells, with a correlated increase in ELOVL2 promoter methylation.
We then asked whether modulating the expression of ELOVL2 could influence cellular aging. First, using shRNA delivered by lentivirus, we knocked down ELOVL2 expression in WI38 and another model cell line, IMR-90, and observed a significant decrease in proliferation rate ( Fig. S2A, B) , an increased number of senescent cells in culture as detected by SA-β-Gal staining (Fig 2C and Fig. S2E ), and morphological changes consistent with morphology of high PD cells (Fig. S2F) . Altogether, these data suggest that decreasing ELOVL2 expression results in increased aging and senescence in vitro.
Next, we tested whether we could manipulate Elovl2 expression by manipulating the Elovl2 promoter methylation. We treated WI38 fibroblasts with 5-Aza-2'-deoxycytidine (5-Aza-dc), a cytidine analog that inhibits DNA methyltransferase 22 . Cells were treated for two days with 2 µM 5-Aza-dc followed by a five-day wash-out period. Interestingly, we found that upon treatment with 5-Aza-dc, Elovl2 promoter methylation was reduced ( Fig.   2D ), and Elovl2 expression was upregulated ( Fig. 2E) . Moreover, upon 5-Aza-dc treatment, a lower percentage of senescent cells were observed in culture ( Fig. 2F) . To assess whether the decrease of senescence is caused at least in part by the ELOVL2 function we knocked down the ELOVL2 expression in aged WI38 cells and treated them with 5-Aza-dc as previously described. Again, significantly lower proportion of senescent cells was detected upon the drug treatment, but the effect of drug treatment was significantly reduced by shRNA-mediated knockdown of ELOVL2, using either of two ELOVL2 shRNAs compared to a control shRNA ( Figure S2B ). This indicates an important role of ELOVL2 in the process. Altogether, these data suggest that the reversing ELOVL2 promoter methylation increases its expression and decreases senescence in vitro.
DNA demethylation in the retina by intravitreal injection of 5-Aza-dc increases Elovl2 expression and rescues age-related changes in scotopic function in aged mice
We next explored whether demethylation of the Elovl2 promoter could have similar effects on Elovl2 expression in vivo. To accomplish this, we performed intravitreal injection of 5-Aza-dc, known to affect DNA methylation in nondividing neurons 23-25 26 , into aged wildtype mice. 8-month-old C57BL/6J mice were injected with 1 µL of 2 µM 5-Aza-dc in one eye and 1 µL of PBS in the other eye as a control, every other week over a period of 3 months (total of 5 injections) ( Fig. 2G) . After the treatment, tissues were collected, and RNA and DNA were extracted. We found, using the MeDIP method, that methylation of the Elovl2 promoter decreased after treatment ( Fig. 2H) , with a corresponding upregulation of Elovl2 expression ( Fig. 2I) . Notably, we observed that the scotopic response was significantly improved in the 5-Aza-dc injected eyes compared to vehicle controls ( Fig. 2J) . These data show that DNA demethylation, which included demethylation of the Elovl2 promoter region, influence and potentially delay age-related changes in visual function in the mouse retina.
Elovl2 C234W mice demonstrate a loss of ELOVL2-specific enzymatic activity.
We next sought to investigate the in vivo function of Elovl2 in the retina. Since C57BL/6
Elovl2 +/-mice display defects in spermatogenesis and are infertile 27 , we developed an alternative strategy to eliminate ELOVL2 enzymatic activity in vivo. Using CRISPR-Cas9 technology, we generated Elovl2-mutant mice encoding a cysteine-to-tryptophan substitution (C234W). This mutation selectively inactivates enzymatic activity of ELOVL2 required to process C22 PUFAs, to convert docosapentaenoic acid (DPA) (22:5n-3) to 24:5n-3, while retaining elongase activity for other substrates common for ELOVL2 and the paralogous enzyme ELOVL5 (Fig. 3A, Fig. S3A ) 9, 28, 29 . A single guide RNA against the Elovl2 target region, a repair oligonucleotide with a base pair mutation to generate the mutant C234W, and Cas9 mRNA were injected into C57BL/6N mouse zygotes ( Fig. 3B) .
One correctly targeted heterozygous founder with the C234W mutation was identified. No off-target mutations were found based on DNA sequencing of multiple related DNA sequences in the genome. (Fig. S3B) . The C234W heterozygous mice were fertile, and C234W homozygous mice developed normally and showed no noticeable phenotypes.
We analyzed the long chain fatty levels in the retinas of homozygous Elovl2 C234W mice to determine whether there was a loss of enzymatic activity specific to ELOVL2. We observed that Elovl2 C234W mice had higher concentrations of C22:5 fatty acid (a selective substrate of ELOVL2 elongation) and lower levels of C24:5 (primary product of ELOVL2 enzymatic activity) and C22:6 (DHA -the secondary product of ELOVL2) ( Fig. 3C) . We also observed similar changes in fatty acid levels in livers of Elovl2 C234W mice as well as lower levels of longer fatty acids that require primary product of Elovl2 as a substrate ( Fig.   S4 ) This suggests that the Elovl2 C234W mice have altered ELOVL2 substrate specificity and inhibited ELOVL2-specific C22 elongase activity.
Loss of ELOVL2-specific activity results in early vision loss and accumulation of subRPE deposits
We next investigated whether the Elovl2 C234W mutation affected the retinal structure and/or function in vivo. First, we observed a significant number of autofluorescent spots on fundus photography in animals at six months of age, which were not found in wild-type littermates (Fig 4A, B ). This phenotype was consistently observed in 6, 8, and 12-month old mutant animals and in both animal sexes, but the phenotype was consistently more pronounced in male mice ( Fig. S5) . Importantly, ERG analysis revealed that 6-month old Elovl2 C234W mice displayed a decrease in visual function as compared to wild type littermates ( Fig. 4C, Fig. S5 ).
To determine the impact of the mutation on the morphology of the retina on the microscopic level, we performed an immunohistological analysis of tissue isolated form wild type and Elovl2 C234W littermates. Although we did not observe gross changes in morphology of the retinas in mutant animals, we have observed the presence of small aggregates underneath the RPE and found that these subRPE aggregates contained the complement component C3 as well as the C5b-9 membrane attack complex, proteins found in human drusenoid aggregates ( Figure 4D ). In addition, in the mutant subRPE aggregates, we also identified other components found in human deposits such as HTRA1 30 , oxidized lipids T-15 31 , and ApoE, an apolipoprotein component of drusen 32 (Figure 4E ). This suggests that the subRPE deposits found in the Elovl2 C234W mouse contain some drusen-specific components found in early nonexudative AMD. Taken together, these data implicate ELOVL2-specific activity as a potential functional target in age-related eye diseases.
DISCUSSION
ELOVL2 as a critical regulator of molecular aging in the retina
This work is the first demonstration, to our knowledge, of a functional role for Elovl2 in regulating age-associated phenotypes in the retina. Methylation of the promoter region of ELOVL2 is well established as a robust prognostic biomarker of human aging 7,33 , but whether ELOVL2 activity contributes to aging phenotypes had not yet been documented.
In this work, we demonstrated that the age-related methylation of regulatory regions of Elovl2 occurs in the rodent retina and results in age-related decreases in the expression of Elovl2. We show that inhibition of ELOVL2 expression by transfection of ELOVL2 shRNA in two widely-used cell models results in increased senescence and decreased proliferation, endpoints associated with aging. Conversely, we show that the administration of 5-Aza-dc leads to demethylation of ELOVL2 promoter and prevents cell proliferation and senescence compared to controls.
Next, we explored whether Elovl2 expression affected age-related phenotypes in vivo.
Intravitreal injection of 5-Aza-dc in rodents increased Elovl2 expression and reversed age-related changes in visual function by ERG. Next, we showed a decrease in visual function as assessed by ERG as well as increased accumulation of autofluorescent white spots in Elovl2 C234W mice, with ELOVL2-specific activity eliminated, compared to littermates controls. These physiologic and anatomic phenotypes are well-established markers of aging in the mouse retina, suggesting that loss of Elovl2 may be accelerating aging on a molecular level in the retina. Finally, in Elovl2 C234W mice, we observed the appearance of sub-RPE deposits, which colocalize with markers found in human drusen in macular degeneration, a pathologic hallmark of a prevalent age-related disease in the eye. Taken together, we propose that Elovl2 plays a critical role in regulating a molecular aging in the retina, which may have therapeutic implications for age-related eye diseases.
Methylation of the regulatory region as a mechanism of age-dependent gene expression.
DNA methylation at the 5-position of cytosine (5-methylcytosine, 5mC) is catalyzed and maintained by a family of DNA methyltransferases (DNMTs) in eukaryotes 34 and constitutes ~2-6% of the total cytosines in human genomic DNA (28) . Alterations of 5mC patterns within CpG dinucleotides within regulatory regions are associated with changes in gene expression 21, 35 . Recently it has been shown that one can predict human aging using DNA methylation patterns. In particular, increased DNA methylation within the CpG island overlapping with the promoter of ELOVL2 was tightly correlated with the age of the individual 33 . We attempted to demethylate this region using 5-Aza-dc, known to inhibit the function of DNMTs also in nondividing neurons [23] [24] [25] . We reported that upon intravitreal injection of the compound, the DNA methylation is reduced, gene expression is upregulated, and visual function is maintained in the treated eye compared with the contralateral control. These data suggest that Elovl2 is actively methylated by enzymes inhibited by 5Aza-dc and that age-related methylation either directly or indirectly regulates Elovl2 expression. Further studies are needed to fully address the directness and specificity of methylation effects on Elolv2 expression and visual function.
A molecular link between long-chain PUFAs in age-related eye diseases
Our data show that Elovl2 C234W animals display accelerated loss of vision and the appearance of macroscopic autofluorescent spots in fundus images. The exact identity of such spots in mouse models of human diseases is unclear, as they have been suggested to be either protein-rich, lipofuscin deposits or accumulating microglia 17, 36 .
Rather than deciphering the identity of these macroscopic spots, we used the phenotype as a potential sign of age-related changes in the retina, as suggested by others 17,37 .
The composition of aggregates visible on the microscopic level in sub-RPE layers in the retina is potentially informative with regard to human parallels. Using immunofluorescence we observed the accumulation of several proteins described previously as characteristic for drusen in human AMD samples. Although, our analysis did not exhaust the documented components of drusen in human disease 38 , nevertheless, our data show the appearance of these subRPE deposits, even in the absence of known confounding mutations or variants correlating with the risk of the disease.
What may be the mechanism by which Elovl2 activity results in drusen-like deposits and loss of visual function? ELOVL2 plays an essential role in the elongation of long-chain (C22 and C24) omega-3 and omega-6 polyunsaturated acids (LC-PUFAs) (Fig. 3A) . LC-PUFAs are found primarily in the rod outer segments and play essential roles in retinal function. These PUFAs include both long chain omega-3 (n-3) and omega-6 (n-6) fatty acids such as docosahexaenoic acid (DHA) and arachidonic acid (AA). DHA is the major polyunsaturated fatty acid found in the retina and has been shown to play diverse roles in photoreceptor function, protection in oxidative stress, as well as retinal development 39 .
While DHA has been well studied in the human retina, the function of other LC-PUFAs in the ELOVL2 elongation pathway is unknown. Further experiments to dissect the roles of specific LC-PUFAs in this pathway, and which of these lipid species are implicated in this phenotype are still required.
Multiple lines of evidence have linked PUFAs to age-related macular degeneration (AMD). AMD is the leading cause of blindness in developed countries 40 Analysis of AMD donor eyes showed decreased levels of multiple LC-PUFAs and VLC-PUFAs in the retina and RPE/choroid compared to age-matched controls 41 .
Epidemiologic studies suggest that low dietary intake of LC-PUFAs such as omega-3 fatty acids was associated with a higher risk of AMD 42, 43 . Furthermore, mutations in ELOVL4, a key enzyme in the synthesis of VLC-PUFAs, have been identified in Stargardt-like macular dystrophy (STGD3), a juvenile retinal dystrophy with macular deposits reminiscent of AMD [44] [45] [46] . Despite the biochemical, epidemiologic, and genetic evidence implicating PUFAs in AMD, the molecular mechanisms by which LC and VLC-PUFAs are involved in drusen formation, and AMD pathogenesis are still poorly understood. The finding that loss of ELOVL2 activity results in early accumulation of subRPE deposits strengthens the relationship between PUFAs and macular degeneration. Since Elovl2 is expressed in both photoreceptors and RPE, whether these phenotypes of visual loss and subRPE deposits are due to cell autonomous function in the photoreceptors and RPE respectively or require interplay between photoreceptors and RPE still needs to be established.
Conclusions
In summary, we have identified the lipid elongation enzyme ELOVL2 as a critical component in regulating molecular aging in the retina. Futher studies may lead to a better understanding of molecular mechanisms of aging in the eye, as well as lead to therapeutic strategies to treat a multitude of age-related eye diseases.
METHODS
Cell culture and treatment.
WI38 and IMR-90 human fibroblasts were cultured in EMEM (ATCC) supplemented with 10% fetal bovine serum (Omega) and 1% penicillin/streptomycin (Gibco), and kept in a humidified incubator at 5% CO2 and 37°C. Confluence was calculated via ImageJ imaging software, including three fields of view per sample (10x). Upon confluence, cells were split and seeded at a 1:3 ratio. Population doublings (PD) were calculated by cell count.
Knockdown lentivirus was generated using MISSION shRNA (Sigma) according to the manufacturer's instructions. 5-Aza-2'-deoxycytidine was purchased from TSZ Chem (CAS#2353-33-5) and dissolved in cell culture medium at a concentration of 2µM. Cells were treated every day for a period of 48 hours. The medium was then replaced with regular cell culture medium, and the cells were cultured for 5 more days.
Senescence-associated β-galactosidase (SA-β-gal) activity.
The SA-β-gal activity in cultured cells was determined using the Senescence β-Galactosidase Staining Kit (Cell Signaling Technology), according to the manufacturer's instructions. Cells were stained with DAPI afterward, and percentages of cells that stained positive were calculated with imaging software (Keyence), including three fields of view (10x).
Nucleic acid analysis.
DNA and RNA were isolated from human fibroblasts and mouse tissues with TRIzol Supplementary Table 1 Western Blotting.
10μg of total protein isolated with TRIzol (Invitrogen) from retinas of WT mice of varying stages of development was subject to SDS-PAGE followed by Western blotting (see Supp. Table 2 for antibodies used in the study). H3 served as loading control..
Quantification of Western blots
WB ECL signals were imaged using BioRad ChemiDoc system. Background-subtracted signal intensities were calculated using ImageJ separately for ELOVL2 bands and H3 loading-control bands. ELOVL2 levels were calculated by dividing ELOVL2 signals by corresponding H3 signals, and then normalized to E15.5.
RNAscope ® In situ hybridization
In situ hybridization was performed using the RNAscope ® Multiplex Fluorescent Assay v2 (ACD Diagnostics,Newark, CA). Mouse Elovl2 Rpe65 and Arr3 probes (p/n 542711, p/n frozen histologic sections of mouse eyes were pretreated per manual using hydrogen peroxide and target retrieval reagents such as protease IV. Probes were then hybridized according to the protocol and then detected with TSA Plus  Fluorophores Fluorescein, Cyanine 3 and Cyanine 5 (Perkin Elmer, Waltham MA). Sections were mounted with DAPI and Prolong Gold antifade (ThermoFisher, Waltham, MA) with coverslip for imaging and imaged (Keyence BZ-X700).
CRISPR-Cas9 design.
CRISPR-Cas9 reagents were generated essentially as described 47 and validated in our facility 48 . T7 promoter was added to cloned Cas9 coding sequence by PCR amplification.
The T7-Cas9 product was then gel purified and used as the template for in vitro transcription (IVT) using mMESSAGE mMACHINE T7 ULTRA kit (Life Technologies). T7 promoter and sgRNA sequence was synthesized as a long oligonucleotide (Ultramer, IDT) and amplified by PCR. The T7-sgRNA PCR product was gel purified and used as the template for IVT using the MEGAshortscript T7 kit (Life Technologies). A repair template encoding the C234W variant was synthesized as a single stranded oligonucleotide (Ultramer, IDT) and used without purification. Potential off-targets were identified using Cas-OFFinder 49 , selecting sites with fewest mismatches (http://www.rgenome.net/cas-offinder/). The founder mouse and all F1 mice were sequenced for off-targets. List of primers is in Supplementary table 1.
Animal injection and analysis.
All animal procedures were conducted with the approval of the Institutional Animal Care Committee at the University of California, San Diego (protocol number S17114).
CRISP/Cas9 injection. C57BL/6N mouse zygotes were injected with CRISPR-Cas9
constructs. Oligos were injected into the cytoplasm of the zygotes at the pronuclei stage.
Mice were housed on static racks in a conventional animal facility and were fed ad libitum with Teklad Global 2020X diet.
Genotyping, mice substrains. To test for the potentially confounding Rd8 mutation, a mutation in the Crb1 gene which can produce ocular disease phenotypes when homozygous, we sequenced all mice in our study for Rd8. C57BL/6J mice in the aging part of the study were purchased from the Jax laboratory and confirmed to be negative for mutation in Crb1 gene. All C234W mutant animals and their littermates were heterozygous for Rd8 mutation. To test RPE65 gene, all animals were tested for the presence of the variants. All animals in the study harbor homozygous RPE65 variant Leu/Leu. Autofluoresence imaging was performed using the Spectralis  HRA+OCT scanning laser ophthalmoscope (Heidelberg Engineering, (Franklin MA) as previously described (16) using blue light fluorescence feature (laser at 488 nm, barrier filter at 500 nm). Using a 55 degree lens, projection images of 10 frames per fundus were taken after centering around the optic nerve. The image that was most in focus was on the outer retina was then quantified blindly by two independent individuals. Electroretinograms (ERGs) were performed following a previously reported protocol 51 .
Briefly, mice were dark-adapted for 12 h, anesthetized with a weight-based intraperitoneal injection of ketamine/xylazine, and given a dilating drop of Tropicamide (1.5%, Alcon) as well as a drop of Proparacaine (0.5%, Bausch & Lomb) as analgesic. Mice were examined with a full-field Ganzfeld bowl setup (Diagnosys LLC), with electrodes placed on each cornea, with a subcutaneous ground needle electrode placed in the tail, and a reference electrode in the mouth (Grass Telefactor, F-E2). Lubricant (Goniovisc 2.5%, HUB Pharmaceuticals) was used to provide contact of the electrodes with the eyes.
Amplification (at 1-1,000 Hz bandpass, without notch filtering), stimuli presentation, and data acquisition are programmed and performed using the UTAS-E 3000 system (LKC Technologies). For scotopic ERG, the retina was stimulated with a xenon lamp at -2 and -0.5 log cd·s/m2. For photopic ERG, mice were adapted to a background light of 1 log cd·s/m2, and light stimulation was set at 1.5 log cd·s/m2. Recordings were collected and averaged in manufacturer's software (Veris, EDI) and processed in Excel.
Immunostaining. Eyeballs were collected immediately after sacrificing mice, fixed in 4% paraformaldehyde for 2 hours, and stored in PBS at 4°C. For immunostainings, eyeballs were sectioned, mounted on slides, then incubated with 5% BSA 0.1% Triton-X PBS blocking solution for 1 hour. Primary antibodies (see Supp. Table 2 for antibodies used in the study) were added 1:50 in 5%BSA PBS and incubated at 4°C for 16 hours.
Following 3x PBS wash, secondary antibodies were added 1:1000 in 5%BSA PBS for 30 minutes at room temperature. Samples were then washed 3x with PBS, stained with DAPI for 5 minutes at room temperature, mounted, and imaged (Keyence BZ-X700). To explore methylation of the promoter region of ELOLV2, we first designated the promoter as -1000bp to +300bp with respect to the strand and transcription start site (TSS) and then identified profiled methylation CpGs using BEDtools (v2.25.0) 57 . We then binned each profiled CpG in the promoter region according to 30bp non-overlapping windows considering CpGs with at least 5 reads. We then grouped the 136 C57BL/6 control mice according to five quantile age bins, and took the average methylation for each age bin and each window. All analysis was performed using custom python (version 3.6) scripts, and plots were generated using matplotlib and seaborn.
To explore the homologous region in humans, we accessed human blood methylome data generated using the Human Illumina methylome array downloaded from GEO, using accessions GSE36054 58 and GSE40279 2 for a total of 736 samples. Methylation data were quantile normalized using Minfi 59 and missing values were imputed using the Impute package in R. These values were adjusted for cell counts as previously described 5 . To enable comparisons across different methylation array studies, we implemented beta-mixture quantile dilation (BMIQ) 5, 60 and used the median of the Hannum et al. dataset as the gold standard 2 .
We then identified probes within the promoter region of ELOLV2 in the human reference (hg19, UCSC), identifying 6 total probes in the commonly profiled region. We then grouped the 787 individuals according to 5 quantile age bins and grouped probes into 10bp non-overlapping windows. These data were then analyzed and plotted identically as for mice. Table S2 
